Tom Shepherd
Dr. Tom Shepherd is Chief Executive Officer of Captor Therapeutics, a drug discovery company focused on Targeted Protein Degradation listed on the Warsaw Stock Exchange since its IPO in 2021, with laboratory facilities in Poland and in Switzerland.
Tom has a Ph.D. in Biochemistry from the University of Strathclyde in his native Scotland. Following an early career in the Medical Department of Novartis, he has since primarily worked in Business Development and General Management roles internationally in drug discovery companies in the UK, California, France, Australia, and Switzerland, including with Bausch-Health and Kymab, prior to joining Captor Therapeutics in Poland in 2019.
Thomas Hayhow
Sara Pannilunghi
Sara Pannilunghi received her degree in Pharmacy with a Master in Pharmaceutical Chemistry and Technology from the University of Bologna (Italy) in 2018. After a brief experience with the solid-state synthesis of anti-VEGF peptides (Paris Descartes University), she contributed during her Master’s thesis to developing novel α-Carboline inhibitors of the Anaplastic Lymphoma Kinase (University of Geneva). In late 2018, Sara started a Ph.D. in Medicinal Chemistry and Biochemistry in Prof. L. Scapozza’s group at the University of Geneva. Her current project focuses on the conception, synthesis, and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) employed against drivers of chronic inflammation.
Sandra Kumper
Riccardo De Matos Simoes
Matthias Brand
Leah Fung
Gaoqi Weng
Fu-Sen Liang
